generic
A cheaper, off-patent copy of a brand drug that should enter the market after protection expires but is often blocked by exclusion deals.
As defined in Robin Feldman on Drugs, Money, and Secret Handshakes
Where it comes up · 4
- Robin Feldman on Drugs, Money, and Secret Handshakes2 claims
- Anne-Marie Peterson - The Capital System - [Invest Like the Best, EP.364]2 claims
- Investing in Healthcare1 claim
- Adam Cifu on the Case for Being a Medical Conservative1 claim
Most important claims · 6 of 6Search all claims for “generic” →
- Pharma is only about 10 percent of health care spending yet spends roughly 20 percent of sales on R&D, and its manufacturing complexity creates a moat that blocks generics even after patents expire, as with Vertex in cystic fibrosis.Anne-Marie Peterson - The Capital System - [Invest Like the Best, EP.364]
- Pharma now has a moat against generics because manufacturing is hard to copy, as with Vertex's cystic fibrosis drugs, so companies keep cash flow after patent expiry and reinvest it into new patents and therapies.Anne-Marie Peterson - The Capital System - [Invest Like the Best, EP.364]
- Small incremental improvements—such as a drug absorbed more easily or taken less often—are awarded patent monopolies and priced many-fold above generics, then preferentially prescribed even though the system fails to encourage patients toward equally effective generics, which is a serious flaw of the current arrangement.Adam Cifu on the Case for Being a Medical Conservative
- Breakthrough drugs priced high today will become generic within roughly 20 years as patents expire, so paying up now effectively gives a gift to people in the future who will access them inexpensively.Investing in Healthcare
- All top-selling insulin drugs have extended their protection by at least 20 years, each piling on dozens of protections (one with 55), and these provide the volume positions that set up PBM deals so cheaper generic insulin—even from nonprofits—cannot get into health plan coverage and therefore cannot reach patients, despite insulin being a long-discovered 'magic bullet.'Robin Feldman on Drugs, Money, and Secret Handshakes
- Because prescription drug distribution flows overwhelmingly through health plans, a product not on the formulary won't get filled or substituted at the pharmacy and cannot enter the system, and a cheap-generic maker cannot afford the mass television advertising a brand company uses to reach patients—so getting off the formulary is not a workaround for reaching patients.Robin Feldman on Drugs, Money, and Secret Handshakes